anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The cachexia index is a novel indicator of cachexia, but its prognostic implications for survival outcomes have not been systematically assessed in patients with gastrointestinal cancer. This systematic review and meta-analysis aimed to examine the association between the cachexia index and survival outcomes in gastrointestinal cancer patients. Two independent reviewers searched PubMed, Embase, and Web of Science to identify studies that evaluated the prognostic significance of the cachexia index in patients with gastrointestinal cancer. The prognostic value of the cachexia index was determined by combining the adjusted hazard ratios (HR) and 95% confidence intervals (CI). Thirteen studies were identified, including a total of 4207 patients. Meta-analysis indicated that a lower cachexia index was associated with shorter overall survival (HR 2.18; 95% CI 1.78-2.66) and disease-free survival (HR 1.72; 95% CI 1.50-1.97) in gastrointestinal cancer patients. Further stratified analysis confirmed the significant association between a lower cachexia index and shorter overall survival in different study designs, regions, patients' age, sample sizes, gastrointestinal cancer subtypes, tumor stages, and follow-up duration subgroups. The cachexia index could be utilized as a predictor of overall survival and disease-free survival in patients with gastrointestinal cancer. However, future prospective studies are required to confirm these findings.
This study presents phenomenological features of auditory verbal hallucinations (AVH) in schizophrenia and associated anomalies of experience. The purpose is to compare the lived experience of AVH to the official definition of hallucinations as a perception without object. Furthermore, we wish to explore the clinical and research implication of the phenomenological approach to AVH. Our exposition is based on classic texts on AVH, recent phenomenological studies and our clinical experience. AVH differ on several dimensions from ordinary perception. Only a minority of schizophrenia patients experiences AVH localized externally. Thus, the official definition of hallucinations does not fit the AVH in schizophrenia. AVH are associated with several anomalies of subjective experiences (self-disorders) and the AVH must be considered as a product of self-fragmentation. We discuss the implications with respect to the definition of hallucination, clinical interview, conceptualization of a psychotic state and potential target of pathogenetic research.
A method for providing a customized skin care product to a customer. The method includes obtaining skin information from a consumer regarding current skin conditions. A skin condition is generated in response to the skin information. An ingredient is selected corresponding to the skin condition. A compatibility profile is generated corresponding to all previously selected ingredients. The generating skin conditions, selecting the ingredient and generating the compatibility profile are repeated until a sufficient number of ingredients are selected to provide a formulation that includes a base and at least two booster compositions that, when mixed, form a skin care composition that is stable and has efficacious concentrations of active ingredients corresponding to skin conditions of a consumer. The formulation comprising the ingredients selected is generated and a cosmetic dispensing system dispenses the ingredients of the formulation.
It is essential to identify the subgroup of patients who experience poorer outcomes in order to adapt clinical management effectively. In the context of liver disease, the earlier the identification occurs, the greater the range of therapeutic options that can be offered to patients. In the past, patients with acute decompensation (AD) of chronic liver disease were treated as a homogeneous group, with emphasis on identifying those at the highest risk of death. In the last 15 years, a differentiation has emerged between acute-on-chronic liver failure syndrome (ACLF) and AD, primarily due to indications that the latter is linked to a less favorable short-term prognosis. Nevertheless, the definition of ACLF varies among the different knowledge societies, making it challenging to assess its true impact compared with AD. Therefore, the purpose of this review is to provide a detailed analysis emphasizing the critical importance of identifying ACLF in the field of advanced liver disease. We will discuss the differences between Eastern and Western approaches, particularly in relation to the occurrence of liver failure and disease onset. Common characteristics, such as the dynamic nature of the disease course, will be highlighted. Finally, we will focus on two key clinical implications arising from these considerations: the prevention of ACLF before its onset and the clinical management strategies once it develops, including liver transplantation and withdrawal of care.
Posterior QLB process After aseptic conditions are provided, the convex US probe will be covered with a sterile sheath, and an 80-100 mm block needle will be used. After imaging the abdominal muscles with the anterior approach, the needle will be advanced in the Petit triangle and 1-2 ml of saline will be injected into the posterior border of the quadratus lumborum muscle. After the block location is confirmed, 20 ml of local anesthetic infiltration at a concentration of 0.25% will be applied. The same procedure will be applied to the other side. A total of 30 ml of local anesthetic solution will be used.
An automated system manages completion of a medical imaging study having one or more different reports associated with one or more different personnel. A user interface provides multiple display images. A configuration processor enables a user, using a display image, to assign a predetermined completion status to a report. The predetermined completion status is used to indicate a report is complete as required for an associated imaging study to be designated complete. A monitoring processor monitors stored indicators indicating current status of corresponding reports associated with the imaging study. A decision processor, in response to the monitoring of the stored indicators, automatically determines whether a current status of a report matches a corresponding predetermined completion status of a report for individual reports associated with the imaging study and in response to a match for the individual reports, initiates generation of a message indicating the imaging study is complete.
Nitrates — Administration of ENTADFI to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies, tadalafil was shown to potentiate the hypotensive effect of nitrates. In a patient who has taken ENTADFI, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of ENTADFI before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring [see Contraindications (4), and Clinical Pharmacology (12.2)].

Guanylate Cyclase Stimulators — Administration of ENTADFI to patients taking a guanylate cyclase (GC) stimulator is contraindicated. ENTADFI may potentiate the hypotensive effects of GC stimulators [see Contraindications (4)].

Alpha-Blockers — Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. PDE5 inhibitors, including ENTADFI, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated [see Warnings and Precautions (5.3), and Clinical Pharmacology (12.2)].

Antihypertensives — PDE5 inhibitors, including tadalafil, are mild systemic vasodilators. Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood-pressure-lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendrofluazide, enalapril, and metoprolol). Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.2)].
A method includes receiving patient-generated event data over a network from a patient device associated with a patient having an activated digital therapy prescription for treating an underlying disease or disorder. The patient-generated event data is encrypted by the patient device and includes at least one time-stamped event associated with the activated digital therapy prescription. In response to receiving the patient-generated event data, the method includes decrypting, anonymizing, and storing the anonymized patient-generated event data on memory hardware. The method also includes receiving, over a network from a healthcare provider (HCP) system, a patient record request requesting patient-generated event data and including an authentication token. In response to receiving the patient record request, the method includes retrieving and encrypting anonymized patient-generated event data from the memory hardware using the authentication token. The method also includes transmitting the encrypted patient-generated event data to the HCP system.
Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Patients with pernicious anemia should be informed that they will require monthly injections of vitamin B12 for the remainder of their lives. Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Also, patients should be warned about the danger of taking folic acid in place of vitamin B12, because the former may prevent anemia but allow progression of subacute combined degeneration.  
  
A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any vitamin B12. Patients following such a diet, should be advised to take oral vitamin B12 regularly. The need for vitamin B12 is increased by pregnancy and lactation. Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time.
When an eligible specimen from a patient shows pathogen growth, the pathogen identification will be randomized to either MaldiTof or routine diagnostics ('diagnostic pipelines'). Randomization to MaldiTof or routine diagnostics will be 1:1 with stratification by hospital and specimen type (blood vs. other). Isolates grown from all eligible specimens of the same patient will be assigned to the same diagnostic pipeline as the first randomized specimen of that patient.

Allocation to diagnostic arm will be assigned by a web based randomization program. When a pathogen is isolated from a positive eligible specimen, the laboratory technician will log onto the secure randomization program and enter the patient and specimen code. The random diagnostic pipeline allocation will then be generated, informed to the laboratory technician and logged in the study database. In the case of multiple specimens with pathogen growth for a single patient, the unique patient code will trigger the randomization program to generate the same diagnostic arm allocation as the previous sample(s).
Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs, including SAPHRIS. The risk appears to be highest among the elderly, especially elderly women, but it is not possible to predict which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. 

The risk of tardive dyskinesia and the likelihood that it will become irreversible increase with the duration of treatment and the cumulative dose. The syndrome can develop after a relatively brief treatment period, even at low doses. It may also occur after discontinuation of treatment. 

There is no known treatment for tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, possibly masking the underlying process. The effect that symptomatic suppression has upon the long-term course of tardive dyskinesia is unknown. 

Given these considerations, SAPHRIS should be prescribed in a manner most likely to reduce the risk of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients: 1) who suffer from a chronic illness that is known to respond to antipsychotic drugs; and 2) for whom alternative, effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, use the lowest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. Periodically reassess the need for continued treatment.

If signs and symptoms of TD appear in a patient on SAPHRIS, drug discontinuation should be considered. However, some patients may require treatment with SAPHRIS despite the presence of the syndrome.
This study is designed to evaluate the benefits of three different home-based cardiac rehabilitation (CR) models on the recovery of patients with acute coronary syndrome (ACS). Cardiovascular diseases are a major cause of mortality worldwide, but advancements in CR have significantly improved patient outcomes. Despite the proven benefits of CR in enhancing quality of life and reducing hospital readmission rates, participation in traditional CR programs remains low. Home-based CR, especially using tele-rehabilitation technologies, offers a promising alternative. This randomized controlled trial will recruit 60 ACS patients, divided into three groups: a 12-week home rehabilitation group, a 6-week tele-rehabilitation followed by a 6-week home rehabilitation group, and a 12-week tele-rehabilitation combined with home rehabilitation group. All patients will undergo evaluations at baseline, and at 3, 6, and 12 months to assess physical health, cardiopulmonary function, and psychological well-being. The hypothesis is that home-based CR, particularly with tele-rehabilitation support, will enhance recovery and quality of life more effectively than traditional methods. The findings aim to identify the most effective home rehabilitation strategy for ACS patients, providing insights into improving their cardiopulmonary function and overall well-being.
The subjects who were on a placebo were put on the cream two times per day for 4 weeks. The questionnaire for testing the effects progressed when before using the cream, after 2 weeks, and after 4 weeks.
A 12-month, randomized, parallel, open-label, active-controlled study was conducted in patients with type 1 diabetes to assess the safety and efficacy of HUMALOG (n=81) compared with Humulin ® R [insulin human injection (100 units per mL)] (n=86). HUMALOG was administered by subcutaneous injection immediately prior to meals and Humulin R was administered 30 to 45 minutes before meals. Humulin ® U [ULTRALENTE ® human insulin (rDNA origin) extended zinc suspension] was administered once or twice daily as the basal insulin. There was a 2- to 4-week run-in period with Humulin R and Humulin U before randomization. Most patients were Caucasian (97%). Forty-seven percent of the patients were male. The mean age was 31 years (range 12 to 70 years). Glycemic control, the total daily doses of HUMALOG and Humulin R, and the incidence of severe hypoglycemia (as determined by the number of events that were not self-treated) were similar in the two treatment groups. There were no episodes of diabetic ketoacidosis in either treatment group.
OBJECTIVES: This study aimed to verify the prevalence of sarcopenia and its associations with sociodemographic, clinical and psychological factors in community-dwelling older adults.
STUDY DESIGN: A randomized cross-sectional study was extracted from a probabilistic cluster conducted on individuals aged 65 years or older residing in the community.
METHODS: Sarcopenia was defined according to the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2). Body composition was assessed using dual-energy X-ray absorptiometry (DXA). Associations were analyzed using networks based on mixed graphical models. Predictability indices of the estimated networks were assessed using the proportion of explained variance for numerical variables and the proportion of correct classification for categorical variables.
RESULTS: The study included 278 participants, with a majority being female (61 %). The prevalence of sarcopenia was 39.57 %. Among those with sarcopenia, 67 % were women and 33 % were men. In the network model, age, race, education, family income, bone mass, depression, cardiovascular disease, diabetes, total cholesterol levels and rheumatism were associated with sarcopenia. The covariates demonstrated a high accuracy (62.9 %) in predicting sarcopenia categories.
CONCLUSION: The prevalence of sarcopenia was high, especially in women. In addition, network analysis proved useful in visualizing complex relationships between sociodemographic and clinical factors with sarcopenia. The results suggest early screening of sarcopenia for appropriate treatment of this common geriatric syndrome in older adults in Brazil.
Levonorgestrel 1.5 mg orally x 1 dose. Timing of dosage depends on ovarian follicle measurements.
Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
PCT No. PCT/JP98/03187 Sec. 371 Date Mar. 15, 1999 Sec. 102(e) Date Mar. 15, 1999 PCT Filed Jul. 15, 1998 PCT Pub. No. WO99/03572 PCT Pub. Date Jan. 28, 1999An O/W/O type multiple emulsion in which an O/W type emulsion is dispersed in the outer phase oil wherein the O/W type emulsion in the inner phase contains water, an oil based ingredient, a surfactant and an amphiphilic substance chosen from those which can form a gel at ordinal temperature or higher in an amphiphilic substance-surfactant-oil-water system or N-long chain acyl acidic amino acid monosalt and an amphiphilic substance chosen from those which can form a gel at ordinal temperature or higher in an amphiphilic substance-N-long chain acyl acidic amino acid monosalt-oil-water system, said outer phase oil contains organophilic modified clay minerals and an emulsifying agent with a HLB of 7 or lower, and the weight ratio of the O/W type emulsion and the outer phase oil is 2:3-19:1. An O/W/O type multiple emulsion with superior stability over time and good usability.
Patients receive pemetrexed disodium, carboplatin, and thoracic radiotherapy as in arm I. Patients also receive cetuximab IV over 2 hours on day 1 and then IV over 1 hour on days 8, 15, 22, 29, 36, and 43.
Clindamycin in 5% Dextrose Injection is a sterile solution of clindamycin phosphate with 5% dextrose. It is available in 50 mL clear molded glass vial fitted with an injection stopper. Single-dose vials are intended for single use only and are available as follows:

Exposure of pharmaceutical products to heat should be minimized. 

Storage: Store at 20º to 25ºC (68º to 77ºF) [see USP Controlled Room Temperature]. Avoid temperatures above 30 ºC. 

Discard unused portion.
Participants will receive placebo administered IV on Days 1 and 15 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911.
Platinum compounds are very active in first-line treatments of ovarian carcinoma. In fact, high rates of complete remission are achieved, but most patients eventually relapse with resistant disease. Many mechanisms underlying the platinum-resistant phenotype have been reported. However, there are no data in the same isogenic cell system proficient and deficient in homologous recombination (HR) on platinum-acquired resistance that might unequivocally clarify the most important mechanism associated with resistance. We generated and characterized cisplatin (DDP)-resistant murine ovarian ID8 cell lines in a HR-deficient and -proficient background. Specific upregulation of the NER pathway in the HR-proficient and -resistant cells and partial restoration of HR in Brca1-/--resistant cells were found. Combinations of different inhibitors of the DNA damage response pathways with cisplatin were strongly active in both resistant and parental cells. The data from the ID8 isogenic system are in line with current experimental and clinical evidence and strongly suggest that platinum resistance develops in different ways depending on the cell DNA repair status (i.e., HR-proficient or HR-deficient), and the upregulation and/or restoration of repair pathways are major determinants of DDP resistance.
The invention discloses a novel foot-and-mouth disease virus nano antibody, and belongs to the technical field of biology. The invention obtains the nano antibody with the foot-and-mouth disease virus infection detection and neutralization capability. The Lpro antibody produced after the alpaca is immunized can be used for diagnosing foot-and-mouth disease virus infection. At the same time will 100 TCIDs  50  The foot-and-mouth disease virus, the nano antibody and the laboratory preserved pig immunity 21d vaccine antibody are mixed and reacted for 1h in a 96-well plate, and BHK-21 cells are added. Observed 7d 50% cytopathic wellsThe number, the neutralization titer of the nanobody calculated according to the Reed-Muench method is 1:337, vaccine antibody 1:66 can protect 50% of BHK-21 cells from lesions, and the nano antibody has stronger protective force. In conclusion, the nano antibody provided by the invention has the functions of detection and diagnosis and has wide application prospect.
The invention relates to application of ginkgolic acid in pain alleviation. The ginkgolic acid comprises ginkgo acid, ginkgol, ginkgo diphenol and the like, and can be obtained from an extract of leaves, fruits, testa, rhizomes and the like of ginkgo by a chemical separation method. The pain comprises nerve pain, bone pain, muscle pain, tendon ligament pain, cancer pain and the like. A medicament, a medical instrument, a cosmetic or a disinfectant containing the ginkgolic acid and having a purpose of alleviating pain contains 0.001 to 80 weight percent of ginkgolic acid and pharmaceutically common external preparation matrix or acceptable carrier; and the preparation is any one of pharmaceutical external formulations. Pharmacological experimental research shows that the ginkgolic acid has an obvious effect of improving pain threshold on pain response caused by physical, chemical and cancerous stimulus. Clinical trials show that the ginkgolic acid has a remarkable alleviating effect on various pains and is predominant in curative effect, the effective rate reaches over 95 percent, and the ginkgolic acid is safe in use and does not have side effect.